Quest Diagnostics (DGX) EBT Margin (2009 - 2026)

Quest Diagnostics has disclosed EBT Margin across 18 years of filings, most recently posting 11.54% for Q1 2026.

• EBT Margin for Q1 2026 came in at 11.54%, up 113.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 12.2% (up 54.0% YoY), and the FY2025 annual result was 11.94%, up 4.0% from the prior year.
• EBT Margin came in at 11.54% for Q1 2026 at Quest Diagnostics, down from 11.76% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 17.31% in Q1 2022 to a low of 4.67% in Q4 2022.
• The 5-year median for EBT Margin is 11.88% (2023), against an average of 12.06%.
• Across the five-year window, EBT Margin sank 1887 bps in 2022 and surged 569 bps in 2023, its largest moves.
• Quest Diagnostics' EBT Margin stood at 4.67% in 2022, then surged by 122 bps to 10.36% in 2023, then rose by 10 bps to 11.41% in 2024, then climbed by 3 bps to 11.76% in 2025, then declined by 2 bps to 11.54% in 2026.
• The last three EBT Margin figures came in at 11.54% (Q1 2026), 11.76% (Q4 2025), and 11.65% (Q3 2025), per Business Quant data.